×
About 558 results

ALLMedicine™ POEMS Syndrome Center

Research & Reviews  198 results

Coexistence of primary mediastinal MALT lymphoma and multiple myeloma like POEMS syndro...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875955
Medicine Yin S, Zhou K et. al.

Jan 28th, 2023 - The coexistence of the extranidal marginal zone lymphoma (MZL) of mucosa-associated lymphoid tissue (MALT) and multiple myeloma (MM) is an exceedingly rare situation. The rare situation precludes any evidence-based guidelines for MZL or MM. We pre...

POEMS syndrome presents with a distended abdomen: A case report.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834793
The Journal of International Medical Research; Wang W, Yang G

Jan 11th, 2023 - POEMS syndrome is a rare, serious, multisystem disorder and its diagnosis is frequently missed due to its varied clinical presentation. We report here, a 69-year-old woman with initial complaints of distended abdomen, who was misdiagnosed with tub...

Ixazomib Combined With Autologous Stem Cell Transplantation for POEMS Syndrome: A Case ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830575
Technology in Cancer Research & Treatment; Ma J, Wang X et. al.

Dec 30th, 2022 - Objective: Polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes (POEMS) syndrome is a rare monoclonal plasma cell proliferation disorder. At present, there is no unified treatment for POEMS syndrome. Here, we describe one case wit...

Chronic diarrhea - The poetic masquerade.
https://doi.org/10.4103/jpgm.jpgm_1169_21
Journal of Postgraduate Medicine; Bhattacharjee S, Siyad I et. al.

Nov 10th, 2022 - Chronic diarrhea, by definition, is the passage of loose/liquid stools, with increased frequency (more than three times/day), or an output of over 200 g/day, lasting for a duration of four or more weeks. The clinical approach to identify the cause...

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome
https://clinicaltrials.gov/ct2/show/NCT02921893

Nov 10th, 2022 - PRIMARY OBJECTIVE: I. Normalization of VEGF after 3 cycles of therapy. SECONDARY OBJECTIVES: I. Toxicity and safety of the combination of ixazomib citrate (ixazomib), lenalidomide, and dexamethasone. II. Hematologic response after 3 cycles of ther...

see more →

Clinicaltrials.gov  9 results

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome
https://clinicaltrials.gov/ct2/show/NCT02921893

Nov 10th, 2022 - PRIMARY OBJECTIVE: I. Normalization of VEGF after 3 cycles of therapy. SECONDARY OBJECTIVES: I. Toxicity and safety of the combination of ixazomib citrate (ixazomib), lenalidomide, and dexamethasone. II. Hematologic response after 3 cycles of ther...

Individual Patient Expanded Access IND to Treat Polyneuropathy
https://clinicaltrials.gov/ct2/show/NCT04064983

Jul 28th, 2022 - A screening visit will be conducted to assess the eligibility for this investigation. If the participant qualifies the expanded access program eligibility requirements, he will be treated with the investigational product in the following manner: T...

Treatment of POEMS Syndrome With Daratumumab
https://clinicaltrials.gov/ct2/show/NCT04396496

Jul 22nd, 2022 - This trial investigates the use of DARA, an antibody directed at the human CD38 molecule, for the treatment of patients with POEMS syndrome. This trial will enroll ten subjects, who will complete 12 four-week cycles of DARA, in combination with th...

A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
https://clinicaltrials.gov/ct2/show/NCT05263817

Mar 3rd, 2022 - POEMS syndrome, amyloidosis, autoimmune hemolytic anemia, vasculitis and other diseases may only show local pathological damage or systemic lesions. If they are not diagnosed and treated in time or poorly controlled, they will progress as the cour...

Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia
https://clinicaltrials.gov/ct2/show/NCT04083014

Oct 13th, 2021 - Glucocorticoids are the first-line treatment of warm AIHA. The overall response is 70-90%, but 10% to 20% patients are refractory to GCs and more than 50% patients will relapse after GCs tapering or cessation. Anti-CD20 monoclonal antibody is the ...

see more →

News  11 results

Belantamab Mafodotin to Be Withdrawn From US Market for Relapsed/Refractory Myeloma
https://www.onclive.com/view/belantamab-mafodotin-to-be-withdrawn-from-us-market-for-relapsed-refractory-myeloma

Nov 22nd, 2022 - GlaxoSmithKline (GSK) plc has initiated the process to withdraw the United States marketing authorization for belantamab mafodotin-blmf (Blenrep) for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at le...

Belantamab Mafodotin Fails to Meet PFS End Point in Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/belantamab-mafodotin-fails-to-meet-pfs-end-point-in-relapsed-refractory-multiple-myeloma

Nov 7th, 2022 - Belantamab mafodotin-blmf (Blenrep) did not generate a progression-free survival (PFS) benefit vs the combination of pomalidomide (Pomalyst) plus low-dose dexamethasone, failing to meet the primary end point of the phase 3 DREAMM-3 trial (NCT04162...

FDA Grants Breakthrough Therapy Designation to Elranatamab for Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-elranatamab-for-relapsed-refractory-multiple-myeloma

Nov 3rd, 2022 - The FDA has granted a breakthrough therapy designation to elranatamab (PF-06863135) for the treatment of patients with relapsed/refractory multiple myeloma, according to an announcement from Pfizer.1 The designation is based on 6-month follow-up ...

Melphalan Flufenamide Plus Daratumumab Elicits PFS Benefit in Relapsed/Refractory Myeloma
https://www.onclive.com/view/melphalan-flufenamide-plus-daratumumab-elicits-pfs-benefit-in-relapsed-refractory-myeloma

Oct 26th, 2022 - The combination of melphalan flufenamide (Pepaxto) and daratumumab plus hyaluronidase-fihj (Darzalex Faspro) and dexamethasone elicited an improvement in progression-free survival (PFS) compared with daratumumab and dexamethasone alone in patients...

FDA Grants Orphan Drug Designation to CFT7455 for Multiple Myeloma
https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-cft7455-for-multiple-myeloma

Aug 17th, 2021 - The FDA has granted an orphan drug designation to CFT7455, a MonoDAC degrader targeting IKZF1/3, for use as a potential therapeutic option in patients with multiple myeloma, according to an announcement from C4 Therapeutics, Inc.1 We are pleased ...

see more →

Patient Education  5 results see all →